Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Adoption of new accounting standard	Total Caladrius Biosciences, Inc. Stockholders' Equity	Total Caladrius Biosciences, Inc. Stockholders' Equity Adoption of new accounting standard	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Adoption of new accounting standard	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2018					10,000	9,866,000
Beginning Balance at Dec. 31, 2018	$ 37,454	$ (62)	$ 37,726	$ (62)	$ 0	$ 10	$ 436,433	$ (32)	$ (397,977)	$ (62)	$ (708)	$ (272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(9,502)		(9,507)						(9,507)			5
Unrealized gain (loss) on marketable securities	32		32					32
Share-based compensation (in shares)						96,000
Share-based compensation	663		663				663
Net proceeds from issuance of common stock (in shares)						451,000
Net proceeds from issuance of common stock	1,037		1,037				1,037
Ending Balance (shares) at Jun. 30, 2019					10,000	10,413,000
Ending Balance at Jun. 30, 2019	29,622		29,889		$ 0	$ 10	438,133	0	(407,546)		(708)	(267)
Beginning Balance (shares) at Mar. 31, 2019					10,000	10,393,000
Beginning Balance at Mar. 31, 2019	34,458		34,728		$ 0	$ 10	437,850	(18)	(402,406)		(708)	(270)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(5,137)		(5,140)						(5,140)			3
Unrealized gain (loss) on marketable securities	18		18					18
Share-based compensation (in shares)						0
Share-based compensation	246		246				246
Net proceeds from issuance of common stock (in shares)						20,000
Net proceeds from issuance of common stock	37		37				37
Ending Balance (shares) at Jun. 30, 2019					10,000	10,413,000
Ending Balance at Jun. 30, 2019	29,622		29,889		$ 0	$ 10	438,133	0	(407,546)		(708)	(267)
Beginning Balance (shares) at Dec. 31, 2019					10,000	10,529,000
Beginning Balance at Dec. 31, 2019	20,553		20,816		$ 0	$ 11	438,911	2	(417,400)		(708)	(263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	2,616		2,608						2,608			8
Unrealized gain (loss) on marketable securities	(9)		(9)					(9)
Share-based compensation (in shares)						106,000
Share-based compensation	713		713				713
Net proceeds from issuance of common stock (in shares)						4,950,000
Net proceeds from issuance of common stock	9,683		9,683			$ 5	9,678
Ending Balance (shares) at Jun. 30, 2020					10,000	15,585,000
Ending Balance at Jun. 30, 2020	33,556		33,811		$ 0	$ 16	449,302	(7)	(414,792)		(708)	(255)
Beginning Balance (shares) at Mar. 31, 2020					10,000	10,639,000
Beginning Balance at Mar. 31, 2020	16,984		17,243		$ 0	$ 11	439,330	0	(421,390)		(708)	(259)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	6,602		6,598						6,598			4
Unrealized gain (loss) on marketable securities	(7)		(7)					(7)
Share-based compensation (in shares)						(4,000)
Share-based compensation	294		294				294
Net proceeds from issuance of common stock (in shares)						4,950,000
Net proceeds from issuance of common stock	9,683		9,683			$ 5	9,678
Ending Balance (shares) at Jun. 30, 2020					10,000	15,585,000
Ending Balance at Jun. 30, 2020	$ 33,556		$ 33,811		$ 0	$ 16	$ 449,302	$ (7)	$ (414,792)		$ (708)	$ (255)